Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Janet Griffiths"'
Autor:
Parveen Azan Ali
Publikováno v:
Nursing Older People. 19:22-22
Autor:
Jonathan Corren, Andrew Lindsley, Joseph Spahn, Bill Cook, Janet Griffiths, Nicole Martin, Gene Colice, Ian Pavord
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB194
Autor:
Janet Griffiths, Tuyet-Hang Pham, Eileen Wang, Chris Ambrose, Neil Martin, Jane Parnes, Andrew Lindsley, Gillian Hunter, Gene Colice, John Oppenheimer
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB14
Autor:
Sean Turman, Benjamin Kemp, Ronald Herbst, Janet Griffiths, Jennifer Cann, Mary Jane Hinrichs, M. Jack Borrok, Lisa Marie Kitching Vinall, D. Gareth Rees, David Howe, Yue Wang, Carlos Gonzalez, Shu Wang, Steven Eck, Hong Sun, Brian Naiman, Katherine A. Vousden, Koshu Okubo, Roland Kolbeck, Antonio DiGiandomenico, Tanya N. Mayadas, Gary P. Sims, Ethan Grant, Neang Ly, Ximing Xiong, Yebin Zhou, Srinath Kasturiangan, Holly Koelkebeck, Weiguang Zhao, Christopher Morehouse, Bo Chen
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveImmune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) VIB9600 (previously known as MEDI9600) that blocks IgG i
Autor:
Janet Griffiths, Stephanie L. Roseti, May Mo, Liangwei Wang, Jonathan Corren, Jane R. Parnes, René van der Merwe
Publikováno v:
New England Journal of Medicine. 377:936-946
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody speci
Autor:
Christopher E. Brightling, Gene L. Colice, Sarah Diver, Latifa Chachi, João P Sousa, Paul Newbold, Claire Emson, Gillian Elliott, Janet Griffiths, Richard J. Russell
Publikováno v:
Airway pharmacology and treatment.
Autor:
Wendy I. White, Yuling Wu, Jane R. Parnes, Jennifer Kearley, Wei Zhao, Sriram Sridhar, Janet Griffiths, Tuyet-Hang Pham, Lorin Roskos
Publikováno v:
Airway pharmacology and treatment.
Background: Tezepelumab, a human monoclonal antibody that selectively blocks thymic stromal lymphopoietin interaction (TSLP) with its receptor, improved clinical outcomes vs. placebo in patients with severe, uncontrolled asthma (Phase 2b PATHWAY stud
Publikováno v:
B15. IMMUNOTHERAPY FOR LUNG DISEASE.
Publikováno v:
Clinical Problems.
Background: Tezepelumab, a human anti-thymic stromal lymphopoietin monoclonal antibody, has demonstrated efficacy and safety in a placebo-controlled phase 2b dose-ranging study (Corren J et al. NEJM 2017;377:936-46) in adults with severe uncontrolled
Autor:
May Mo, René van der Merwe, Jonathan Corren, Liangwei Wang, Jane R. Parnes, Stephanie L. Roseti, Janet Griffiths
Publikováno v:
Clinical Problems.
Background: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine and key regulator of inflammatory pathways including type 2 responses. Tezepelumab is a human anti-TSLP monoclonal antibody that reduces the early and late phase asthmatic resp